[The national registry EVASTENT: cost-effectiveness analysis of the sirolimus active stent in diabetic and non-diabetic patients].
Machecourt
J
J
Service de cardiologie, CHU de Grenoble, France. JMachecourt@chu-grenoble.fr
Danchin
N
N
Lablanche
J-M
JM
D003131:Combined Modality Therapy; D023921:Coronary Stenosis / Q000191:economics* / Q000628:therapy*; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications / Q000191:economics* / Q000628:therapy*; D016503:Drug Delivery Systems / Q000191:economics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000191:economics*; D008297:Male; D008875:Middle Aged; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage* / Q000191:economics*; D015607:Stents / Q000191:economics*; D011795:Surveys and Questionnaires
D007166:Immunosuppressive Agents; D020123:Sirolimus